Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia

Palliative care in acute myeloid leukaemia (AML) is inadequate. For elderly patients, unfit for intensive chemotherapy, median survival is 2–3 months. As such, there is urgent demand for low-toxic palliative alternatives. We have repositioned two commonly administered anti-leukaemia drugs, valproic...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Leitch, Calum, Osdal, Tereza, Andresen, Vibeke, Molland, Maren, Kristiansen, Silje, Nguyen, Xuan Nhi, Bruserud, Øystein, Gjertsen, Bjørn Tore, McCormack, Emmet
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2016
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4884979/
https://ncbi.nlm.nih.gov/pubmed/26812881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6991
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller